BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update

Core Viewpoint - BrainStorm Cell Therapeutics Inc. will hold a conference call on August 14, 2024, to update shareholders on Q2 financial results and provide a corporate update [1] Group 1: Conference Call Details - The conference call is scheduled for 8:30 a.m. Eastern Time on August 14, 2024 [1] - Participants can submit questions in advance until 5:00 p.m. Eastern Time on August 12, 2024 [1] - The call can be accessed via toll-free and international numbers, with a specific access code provided [2] Group 2: Company Overview - BrainStorm Cell Therapeutics is focused on developing autologous adult stem cell therapeutics for neurodegenerative diseases [3] - The company holds rights to the NurOwn® technology platform for producing autologous MSC-NTF cells through an exclusive licensing agreement [3] Group 3: Clinical Development - Autologous MSC-NTF cells have received Orphan Drug designation from the FDA and EMA for treating amyotrophic lateral sclerosis (ALS) [4] - A Phase 3 trial for ALS has been completed, investigating the safety and efficacy of repeat-administration of autologous MSC-NTF cells [4] - The company has also completed a Phase 2 open-label multicenter trial for progressive multiple sclerosis (MS) [4]